Factor Xa Inhibitors
Factor Xa Inhibitors - Related Videos
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
02:16
Transcription Factors
0 Views •
2019
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
02:08
Assessing Bacterial Swarming Using a Gradient Inhibitor Plate
0 Views •
2025
Source: Guo, S., et al. Quantifying Bacterial Surface Swarming Motility on Inducer Gradient Plates. J. Vis. Exp. (2022).This video demonstrates the use of a double-layer gradient swarm plate to study bacterial swarming behavior under varying inhibitor concentrations. A plate with a gradient-forming inhibitor in the bottom layer is inoculated with bacteria and incubated. Images are captured at regular intervals to analyze the effect of inhibitor concentration on bacterial swarming.
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
0 Views •
Cited by 4 •
2015
We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.
FAQs
Direct agents act on factor Xa itself, whereas indirect agents reduce factor Xa activity through an intermediary mechanism. In either case, the relevant pharmacologic consequence is less conversion of prothrombin to thrombin. This distinction helps organize the drug class mechanistically, even though both approaches ultimately limit fibrin generation and clot development.
Reducing thrombin matters because it limits a downstream process needed for fibrin generation. With less thrombin available, the coagulation cascade produces less fibrin, which restricts clot development. This explains why factor Xa inhibition can influence clot formation without directly targeting fibrin itself, linking the drug target to the final anticoagulant outcome.
Kidney function, drug interactions, and bleeding risk are central considerations when using these agents. Reduced kidney function or interacting medicines may affect how safely anticoagulation can be maintained, while individual bleeding risk influences the overall treatment assessment. Clinicians therefore evaluate these factors rather than relying only on the drug’s predictable activity.
Their clinical roles include both prevention and treatment of venous thromboembolism and reduction of stroke risk in people with nonvalvular atrial fibrillation. These applications reflect different thromboembolic settings, but the pharmacologic goal remains limiting coagulation sufficiently to reduce harmful clot-related outcomes while accounting for treatment-associated bleeding risk.
Management requires balancing the intended reduction in clot formation against the possibility of bleeding. Kidney function and drug interactions can affect that balance, and clinicians must also consider whether an appropriate reversal strategy is available. These issues are especially important when deciding whether the convenience of oral administration fits the patient’s pharmacologic and clinical circumstances.
Reversal strategy availability is an important part of anticoagulant planning because treatment suppresses a process needed for clot formation. If bleeding risk becomes a concern, clinicians need to account for what reversal options are available when weighing therapy. This consideration complements assessment of kidney function, drug interactions, and the expected benefit of preventing thromboembolic events.